^
Association details:
| Biomarker: | GDF15 overexpression |
|---|---|
| Cancer: | Oral Cancer |
| Drug: | canertinib (CI-1033) (pan-HER inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Mechanism of sensitivity to cisplatin, docetaxel, and 5-fluorouracil chemoagents and potential erbB2 alternatives in oral cancer with growth differentiation factor 15 overexpression
Published date:
12/21/2021
Excerpt:
The results indicated that OSCC cells overexpressing GDF15 were sensitive to TPF through a caspase-9-dependent pathway both in vitro and in vivo....When OSCC cells with GDF15 overexpression were treated with the erbB2 phosphorylation inhibitor, CI-1033, cell proliferation and xenograft growth colony formation were significantly blocked (P < .05)....Thus, ErbB2 inhibitors could represent potential targeted drugs or an alternative therapy for OSCC patients with GDF15 overexpression.
DOI:
10.1111/cas.15218
